![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![Minakem Generic APIs](https://www.pharmacompass.com/image/flap/minakem-header-desktop-w27gif-57924.gif)
![Minakem Generic APIs](https://www.pharmacompass.com/image/flap/minakem-header-mobile-w27gif-62411.gif)
Active Filter(s):
Details:
The partnership with BRC, supports the study of Delta-9 THC products and formulations, allowing OBX to identify the phase appropriate, optimal products for formulations including Delta-9-tetrahydrocannabinol.
Lead Product(s): Tetrahydrocannabinol
Therapeutic Area: Psychiatry/Psychology Product Name: Delta-9 THC
Highest Development Status: Undisclosed Product Type: Small molecule
Partner/Sponsor/Collaborator: Biopharmaceutical Research Company
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration June 14, 2022